<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970004</url>
  </required_header>
  <id_info>
    <org_study_id>ALX-TMA-501</org_study_id>
    <nct_id>NCT04970004</nct_id>
  </id_info>
  <brief_title>Retrospective Observational Study in Adult and Pediatric Patients With HSCT-TMA</brief_title>
  <official_title>A Retrospective Observational Study of Adult and Pediatric Patients With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, retrospective study designed to assess outcomes in patients&#xD;
      diagnosed with hematopoietic stem cell transplant-associated thrombotic microangiopathy&#xD;
      (HSCT-TMA) who were not treated with complement component (C5) inhibitor therapy. Data&#xD;
      required to evaluate study outcomes will be abstracted from the medical records of all&#xD;
      patients who meet study eligibility criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving TMA Response</measure>
    <time_frame>During the 26-week period after HSCT-TMA diagnosis</time_frame>
    <description>TMA Response is defined as platelet count ≥ 50,000/mm^3, lactate dehydrogenase &lt; 1.5 upper limit of normal, absence of schistocytes (if present at baseline), and increase in eGFR ≥ 30% from baseline or discontinuation of dialysis (for patients on dialysis at baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving TMA response</measure>
    <time_frame>During the 52-week period after HSCT-TMA diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in individual components of TMA response</measure>
    <time_frame>From baseline to 26 weeks and to 52 weeks after HSCT-TMA diagnosis</time_frame>
    <description>Platelets, lactate dehydrogenase, eGFR, chronic kidney disease stage, dialysis status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 26 weeks and 52 weeks after HSCT-TMA diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nonrelapse mortality</measure>
    <time_frame>At 26 weeks and 52 weeks after HSCT-TMA diagnosis</time_frame>
    <description>Death due to any cause during the study, with the exception of death due to underlying disease progression or relapse</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Stem Cell Transplant Complications</condition>
  <condition>Thrombotic Microangiopathies</condition>
  <arm_group>
    <arm_group_label>Patients Diagnosed with HSCT-TMA</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No study intervention will be administered as part of this study.</description>
    <arm_group_label>Patients Diagnosed with HSCT-TMA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult and pediatric patients who were diagnosed with TMA within 6 months after a HSCT&#xD;
        procedure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight ≥ 5 kg at the time of HSCT-TMA diagnosis&#xD;
&#xD;
          -  Documented TMA diagnosis within 6 months from the HSCT&#xD;
&#xD;
          -  Evidence of renal dysfunction&#xD;
&#xD;
          -  Presence of hypertension&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of familial or acquired 'a disintegrin and metalloproteinase with&#xD;
             a thrombospondin type 1 motif, member 13' (ADAMTS13) deficiency (activity &lt; 5%)&#xD;
&#xD;
          -  Shiga toxin-related hemolytic uremic syndrome (ST-HUS)&#xD;
&#xD;
          -  Positive direct Coombs test&#xD;
&#xD;
          -  Diagnosis of disseminated intravascular coagulation&#xD;
&#xD;
          -  History or presence of bone marrow/graft failure&#xD;
&#xD;
          -  Diagnosis of veno-occlusive disease&#xD;
&#xD;
          -  Received a complement inhibitor (eg, eculizumab) post-HSCT through 12 months post TMA&#xD;
             diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <phone>855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic Stem Cell Transplant</keyword>
  <keyword>Transplant-associated TMA</keyword>
  <keyword>Thrombotic Microangiopathy (TMA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Thrombotic Microangiopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

